Skip to main content

Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis.

Publication ,  Journal Article
Brown, MA; Zhang, L; Levering, VW; Wu, J-H; Satterwhite, LL; Brian, L; Freedman, NJ; Truskey, GA
Published in: Arterioscler Thromb Vasc Biol
November 2010

OBJECTIVE: To accelerate vein graft reendothelialization and reduce vein graft thrombosis by infusing human umbilical cord blood-derived endothelial cells (hCB-ECs) because loss of endothelium contributes to vein graft thrombosis and neointimal hyperplasia. METHODS AND RESULTS: Under steady flow conditions in vitro, hCB-ECs adhered to smooth muscle cells 2.5 to 13 times more than ECs derived from peripheral blood or human aorta (P<0.05). Compared with peripheral blood and human aorta ECs, hCB-ECs had 1.4-fold more cell surface α(5)β(1) integrin heterodimers per cell (P<0.05) and proliferated on fibronectin 4- to 10-fold more rapidly (P<0.05). Therefore, we used hCB-ECs to enhance reendothelialization of carotid interposition vein grafts implanted in NOD.CB17-Prkdc(scid)/J mice. Two weeks postoperatively, vein grafts from hCB-EC-treated mice demonstrated approximately 55% reendothelialization and no luminal thrombosis. In contrast, vein grafts from sham-treated mice demonstrated luminal thrombosis in 75% of specimens (P<0.05) and only approximately 14% reendothelialization. In vein grafts from hCB-EC-treated mice, 33±10% of the endothelium was of human origin, as judged by human major histocompatibility class I expression. CONCLUSIONS: The hCB-ECs adhere to smooth muscle cells under flow conditions in vitro, accelerate vein graft reendothelialization in vivo, and prevent vein graft thrombosis. Thus, hCB-ECs offer novel therapeutic possibilities for vein graft disease.

Duke Scholars

Published In

Arterioscler Thromb Vasc Biol

DOI

EISSN

1524-4636

Publication Date

November 2010

Volume

30

Issue

11

Start / End Page

2150 / 2155

Location

United States

Related Subject Headings

  • Wound Healing
  • Veins
  • Thrombosis
  • Postoperative Complications
  • Mice
  • Humans
  • Graft Occlusion, Vascular
  • Fetal Blood
  • Endothelium, Vascular
  • Endothelial Cells
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Brown, M. A., Zhang, L., Levering, V. W., Wu, J.-H., Satterwhite, L. L., Brian, L., … Truskey, G. A. (2010). Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. Arterioscler Thromb Vasc Biol, 30(11), 2150–2155. https://doi.org/10.1161/ATVBAHA.110.207076
Brown, Melissa A., Lisheng Zhang, Vrad W. Levering, Jiao-Hui Wu, Lisa L. Satterwhite, Leigh Brian, Neil J. Freedman, and George A. Truskey. “Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis.Arterioscler Thromb Vasc Biol 30, no. 11 (November 2010): 2150–55. https://doi.org/10.1161/ATVBAHA.110.207076.
Brown MA, Zhang L, Levering VW, Wu J-H, Satterwhite LL, Brian L, et al. Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2150–5.
Brown, Melissa A., et al. “Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis.Arterioscler Thromb Vasc Biol, vol. 30, no. 11, Nov. 2010, pp. 2150–55. Pubmed, doi:10.1161/ATVBAHA.110.207076.
Brown MA, Zhang L, Levering VW, Wu J-H, Satterwhite LL, Brian L, Freedman NJ, Truskey GA. Human umbilical cord blood-derived endothelial cells reendothelialize vein grafts and prevent thrombosis. Arterioscler Thromb Vasc Biol. 2010 Nov;30(11):2150–2155.

Published In

Arterioscler Thromb Vasc Biol

DOI

EISSN

1524-4636

Publication Date

November 2010

Volume

30

Issue

11

Start / End Page

2150 / 2155

Location

United States

Related Subject Headings

  • Wound Healing
  • Veins
  • Thrombosis
  • Postoperative Complications
  • Mice
  • Humans
  • Graft Occlusion, Vascular
  • Fetal Blood
  • Endothelium, Vascular
  • Endothelial Cells